Capsugel launches Lipidex platform for greater oral stability, potency

Capsugel, continuing its recent expansion in the drug capsule manufacturing arena, this week launched its new platform Lipidex, which the company says offers greater stability and potency for oral drugs. Capsugel's Dosage Form Solutions (DFS) unit, created earlier this year, developed the platform for use with lipid, liquid and semisolid filling, according to a report from in-PharmaTechnologist.com. Also this year, Capsugel acquired Encap, another manufacturer of lipid-based products for highly potent active pharmaceutical ingredients. Capsugel President Amit Patel said in a statement: "Our Lipidex technology platform provides tailored solutions for the many challenges our customers face, whether it's development of low solubility drugs in their pipeline, repositioning existing drugs for better therapeutic performance or rebranding them using innovative dosage forms." Report | Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…